Massey’s science-driven translational research – moving scientific discoveries from the laboratory into real-world patient applications – is one of the many reasons the National Cancer Institute recently awarded Massey a five-year renewal as one of only two NCI-designated Cancer Centers in Virginia. Often described as “bench-to-bedside” research, translational research involves several stages, including clinical trials, where consenting patients are given drugs, surgical procedures, devices or other interventions to treat cancer and are then closely monitored to determine side effects, effectiveness and other key findings.
Today, as many women as men attend medical school where academic medicine is a career option equally available to all. Yet, of the approximately 125,000 medical school faculty members in the U.S., only 35 percent are women, and until recently, no one knew why.
VCU Massey Cancer Center researcher Steven Grant, M.D., was recently recognized with an appointment to a major cancer journal and continued financial support from the Leukemia and Lymphoma Society, for his world renown work in discovering new therapies for hematological malignancies. Grant is the Shirley Carter Olsson and Sture Gordon Olsson Chair in Oncology Research, associate director for translational research, co-leader and member of the Developmental Therapeutics program and member of the Cancer Cell Signaling program at VCU Massey Cancer Center.
A study published online in the journal Cancer Research details a dramatic increase in multiple myeloma cell death caused by a combination of the drugs obatoclax and flavopiridol. The researchers, led by Steven Grant, M.D., Shirley Carter Olsson and Sture Gordon Olsson Chair in Oncology Research, associate director for translational research, program co-leader and member of Developmental Therapeutics and member of the Cancer Cell Signaling program at VCU Massey Cancer Center, found that the two drugs worked together through different mechanisms to promote a form of cell suicide known as apoptosis.